Fuente: FierceBiotech Emerging ADC development approaches such as bispecific antibodies and dual-payloads are opening new avenues to address heterogeneity and resistance. The next generation of ADCs involve a balance of innovative targets, linkers, conjugation methods, payload MOA, and carriers to build optimized treatments for cancer patients.